Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).Feng Zhang, Shukui Qin, Zhenggang Ren et al.|Journal of Clinical Oncology|2022Cited by 4